{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Foncologypodcast.simplecast.com%2Fepisodes%2Fakt-and-pi3k-inhibitors-breast-cancer-SqsGu6ru","width":444,"version":"1.0","type":"rich","title":"Role of AKT and PI3K Inhibitors in Patients With HR-Positive Breast Cancers: Experts Share Their Thoughts on Current Practice and Future Opportunities","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/165defb8-f7d7-44fe-a7eb-a59f2c35d334/dd94b5e9-26d5-4c07-b387-13672f3c0056/101309_pi3k_akt_mbc_global3000x3000.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/6935e156-672e-4fea-a484-5947fe514151\" height=\"200\" width=\"100%\" title=\"Role of AKT and PI3K Inhibitors in Patients With HR-Positive Breast Cancers: Experts Share Their Thoughts on Current Practice and Future Opportunities\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"Listen to this podcast with Nadia Harbeck, MD, and Francois-Clement Bidard, MD, PhD, sharing their thoughts on the role of AKT and PI3K inhibitors in patients with primary or secondary endocrine-resistant breast cancers."}